一种重组人α1型干扰素突变体IFN-α1/86D的纯化与鉴定

本文研究了重组人α1型干扰素突变体IFN-α1/86D在摇瓶培养和分批发酵培养的重组大肠杆菌DH5α株中的表达动态,并采用阳离子交换层析和抗α1型干扰素单克隆抗体亲和层析的两步流程对其进行了纯化,得到SDS-PAGE纯及高效液相层析(HPLC)纯的IFN-α1/86D产品,共比活性为2.3×10~7单位/毫克蛋白。N端氨基酸序列测定的结果表明,纯化产品的纯度在95％以上,但其N端不均一,产品中含有两种N端序列正确的IFN-α1/86D活性分子,即约75％为去Met分子和约25％为带Met分子。     

人干扰素和脑啡肽融合蛋白的表达和生物学活性

以INFα-m基因为模版,采用overlapping PCR技术构建甲硫氨酸脑啡肽干扰素表达质粒pBV220/Enk-/Met-INFα-m,转化大肠杆菌DH5α表达,产物以包涵体形式存在.包涵体经分离、变性、复性,然后经CM-Sepharose-FF、DEAE-Sepharose-FF离子交换层析和Sephacryal-HR100分子筛纯化,获得较纯的Enk-IFNα-m融合蛋白.生物活性检测表明,融合蛋白不仅具有干扰素的抗病毒、抗增殖、增强NK细胞功能的活性,而且具有脑啡肽的脑内镇痛作用.     

重组人白细胞介素4的纯化及N端氨基酸序列分析

本文对重组人白细胞介素4高效表达克隆pBV220/hIL-4a的表达产物进行了纯化,升对纯化的人IL-4进行了N端氨基酸序列分析。人IL-4基因表达产物在大肠杆菌中以不溶性包涵体形式存在,经过超声破菌、包涵体抽提、复性浓缩、离子交換和凝胶过滤层析一系列纯化步骤,终产物纯度达98％以上,按蛋白总量计算回收率为14％,比活性达2×10~6单位/mg蛋白。通过测定纯化人IL-4的N端16个氮基酸序列,与由其DNA序列推导的氨基酸序列完全一致。本文为重组人IL-4的批量生产奠定了基础。     

人Leptin基因在大肠杆菌中的高效表达、纯化及其生物学活性研究

将人Leptin表达质粒pBV220-OB转化E.coliJM109,经热诱导获得了目的蛋白的表达。经SDS-PAGE鉴定分析,表达产物以包涵体形式存在,目的蛋白表达量占菌体总蛋白的40%以上。通过包涵体分离,Sephacryl S200HR凝胶和DEAE52离子交换层析及Hypersil C18柱反相色谱纯化,获得纯度在95%以上,内毒素含量小于10EU/mg的高纯度的重组人Leptin。Western-blot鉴定表明,纯化表达产物能和抗Leptin抗体特异性结合;蛋白质N端15个氨基酸序列分析结果和预期的序列一致。纯化产物经复性处理,其分子中Cys96和Cys146形成二硫键。体内活性检测显示,纯化和复性的rh-Leptin明显抑制BALB/c小鼠的进食和体重增长,提示其具有明显的生物学活性。     

猪α1-干扰素的基因改造与高效原核表达

poIFNα1基因中含有大量的大肠杆菌稀有密码子,为了获得高表达,使用了大肠杆菌的偏爱密码子,人工合成了poIFN|α1成熟蛋白编码基因。在保留编码蛋白序列的同时,使其5′端A+T的含量增加到最大限度,并将其终止密码子改为TAA。将合成的poIFNα1成熟蛋白编码基因插入原核单纯表达载体pRLC中,转化大肠杆菌DH5α。实现了poIFNα1在大肠杆菌中的高效表达,表达产物以包涵体形式存在。纯化的包涵体经含DTT的6 mol/L盐酸胍的变性液溶解及含GSHGSSG的复性液复性处理,复性后的表达产物浓缩后经凝胶层析纯化,细胞病变抑制法测定表明,重组poIFNα1具有较高的抗病毒活性,约为6.4x10⁶u/mg。      

大肠杆菌表达的重组人GM-CSF的纯化

本文对重组人粒细胞-巨噬细胞集落刺激因子(rhGM-CSF)高效表达克隆pZW.GM的表达产物进行纯化,并对纯化的人GM-CSF进行了N端氨基酸序列分析。人GM-CSF基因表达产物在大肠肝菌中以不溶性包涵体形式存在,经超声破菌、包涵体抽提、凝胶过滤层析、复性、离子交换一系列纯化步骤,终产物纯度达99％,按蛋白总量计算回收率达10％,比活性达1×10~7u/mg蛋白质。通过测定纯化人GM-CSF的N端16个氨基酸序列,与由其DNA序列推导的氨基酸序列完全一致。     

人SCF非融合蛋白的纯化及生物活性

将构建的可溶性SCF表达质粒PBV-SCF转化到大肠杆菌DH5α中进行非溶合蛋白表达,经克隆筛选出高效表达菌株表达量在20％左右,大量扩增后经包涵体提取、液相层析技术纯化,得到纯度为90％以上的rh-SCF制品,对其等电点和N端氨基酸进行分析,证实具有天然SCF特性,生物活性检测表明该表达产物比活性为6.6×10⁵ U/mg, 同时可以协同GM-CSF促进人骨髓中CFU-GM增殖. 重组人可溶性SCF的获得对于实验室研究和临床应用具有一定价值.     

重组人IL-4大肠杆菌表达与纯化

根据大肠杆菌密码子偏爱性优化并合成人白细胞介素4基因,以pET30a( )为载体构建了重组表达质粒pET30a( )/rhIL-4,将重组质粒转化大肠杆菌BL21(DE3)感受态细胞,诱导表达并超声破菌检测重组蛋白的表达形式。采用5L发酵罐培养工程菌,发酵液OD600为0.6时诱导3.5h收集菌体,检测目的蛋白的表达量。收集的菌体经压榨破菌获得包涵体,通过包涵体变性、层析、透析复性等方法对rhIL-4进行纯化。采用人红细胞白血病细胞(TF-1)测定纯化的rhIL-4的生物活性。测序表明目的基因已插入载体pET30a( )中,重组蛋白以包涵体形式表达,单位体积重组蛋白的表达量达200mg/L发酵液,建立了对包涵体形式表达的rhIL-4纯化方法,最终得率为40mg/L发酵液,纯度大于98%,回收率为20%以上。免疫印迹法检测诱导表达的重组蛋白和纯化的蛋白为IL-4,N端氨基酸序列测定结果与理论相符,生物活性检测纯化的蛋白比活性达2.5×106AU/mg。这为rhIL-4进一步产业化研究建立了基础。     

人干扰素ω(huIFN-ω)的高效表达、纯化及生物学活性

为了获得人干扰素-ω(huIFN-ω)在大肠杆菌中的高效表达,根据大肠杆菌的偏爱密码子,人工设计并合成了huIFN-ω高表达基因,并克隆到原核表达载体pBV220,在大肠杆菌DH5α中实现了高效表达,目的蛋白占细胞总蛋白的15%左右,以包涵体形式存在.表达产物经变性、复性及阳离子和分子筛层析纯化,纯度达90%以上,产物的抗病毒活性约为1.0×108IU/mg,并具有体外促NK杀伤活性.此结果为进一步研究和开发重组huIFN-ω奠定了基础.     

干扰素-β1b的高效表达、纯化及抗病毒活性研究

IFN-β1b是大肠杆菌产生的17位Cys被Ser替换的人IFN-β的类似物,为了获得高表达,使用了大肠杆菌的偏爱密码子,人工合成了IFN-β-1b基因,插入质粒pBV220中,转化大肠杆菌DH5α.IFN-β1b的制备过程,包括发酵和一系列的纯化步骤.经修饰,IFN-β1b基因在启动子PRPL控制下发酵表达,合成的蛋白质以包涵体的形式存在.培养的细菌经收集、裂解后,将包涵体释放出来,包涵体经含SDS的溶液溶解,DTT还原.纯化过程包括有机溶剂抽提、分子筛层析、脱盐、氧化复性和反相层析,并用旋转蒸发除去有机溶剂.IFN-β-1b在不同种系来源的细胞上显示不同的抗病毒活性.     

Purification and characterization of the active serine: pyruvate aminotransferase of rat liver mitochondria expressed in Escherichia coli

In the previous study (Oda, T., et al. (1985) Eur. J. Biochem. 150, 415-421), we isolated a cDNA clone which expressed in Escherichia coli a specific size of product having the activity of rat liver serine:pyruvate aminotransferase (SPTm). This specific product (SPT10) was purified to homogeneity through three different column chromatographies. The amino acid composition and N-terminal amino acid sequence of the purified enzyme agreed with those predicted from the nucleotide sequence of cDNA and showed that SPT10 consists of the whole amino acid sequence of mature SPTm and several extra amino acid residues at the N-terminus. The catalytic and physical properties of SPT10, such as substrate specificity, Km for alpha-keto acids, electric charge, and quaternary structure, were all very similar to those of SPTm. Using several cDNA clones which lack a 5'-terminal sequence corresponding to a portion of the N-terminal amino acid sequence of SPTm, we examined the expression profile of the specific product in bacteria transformed with each cDNA clone. The products encoded by these cDNAs were segregated into inclusion bodies and were neither catalytically active nor easily solubilized by sonication. In contrast, the inclusion bodies were not formed in the bacteria transformed with the cDNA clone for SPT10.     

Overproduction of microbial transglutaminase in Escherichia coli, in vitro refolding, and characterization of the refolded form

(MTG) The Streptoverticillium transglutaminase gene, synthesized previously for yeast expression, was modified and resynthesized for overexpression in E. coli. A high-level expression plasmid, pUCTRPMTG-02(+), was constructed. Furthermore, to eliminate the N-terminal methionine, pUCTRPMTGD2 was constructed. Cultivation of E. coli transformed with pUCTRPMTG02(+) or pUCTRPMTGD2 yielded a large amount of MTG (200-300 mg/liter) as insoluble inclusion bodies. The N-terminal amino acid residue of the expressed protein was methionine or serine (the second amino acid residue of the mature MTG sequence), respectively. Transformed E. coli cells were disrupted, and collected pellets of inclusion bodies were solubilized with 8 M urea. Rapid dilution treatment of solubilized MTG restored the enzymatic activity. Refolded MTG, purified by ion-exchange chromatography, which had an N-terminal methionine or serine residue, showed activity equivalent to that of native MTG. These results indicated that recombinant MTG could be produced efficiently in E. coli.     

Molecular cloning, sequencing, and expression of a fibrinolytic serine-protease gene from the earthworm Lumbricus rubellus

The full-length cDNA of the lumbrokinase fraction 6 (F6) protease gene of Lumbricus rubellus was amplified using an mRNA template, sequenced and expressed in E. coli cells. The F6 protease gene consisted of pro- and mature sequences by gene sequence analysis, and the protease was translated and modified into active mature polypeptide by N-terminal amino acid sequence analysis of the F6 protease. The pro-region of F6 protease consisted of the 44 residues from methionine-1 to lysine-44, and the mature polypeptide sequence (239 amino acid residues and one stop codon; 720 bp) started from isoleucine-45 and continued to the terminal residue. F6 protease gene clones having pro-mature sequence and mature sequence produced inclusion bodies in E. coli cells. When inclusion bodies were orally administrated rats, generated thrombus weight in the rat's venous was reduced by approximately 60 % versus controls. When the inclusion bodies were solubilized in pepsin and/or trypsin solutions, the solubilized enzymes showed hemolytic activity in vitro. It was concluded the F6 protease has hemolytic activity, and that it is composed of pro- and mature regions.     

Prokaryotic overexpression of TEV–rhGH and characterization of its polyclonal antibody

Recombinant protein technology represents one of the best solutions to achieve rapid, efficient, and cost-effective protein expression and purification of therapeutic proteins. Growth hormone (GH) is an excellent example of these proteins used in the therapy of hormone deficiencies. In this work, a plasmid, pRSET–TEV–rhGH, has been constructed to overexpress recombinant human GH (rhGH) by cloning its gene downstream of an N-terminal 6 × His-tagged polypeptide (43 aa) in the T7 promoter-plasmid pRSET. This polypeptide was cleavable by means of the integrated recognition site for the tobaccos etch virus (TEV) protease, resulting in an rhGH protein at an exact length and sequence. After IPTG induction, this plasmid effectively expressed TEV–rhGH protein (27 kDa) in the cytoplasm of Escherichia coli, which accumulated in the form of inclusion bodies. The 6 × His-tagged protein, with a yield of ~ 150 mg/L of culture, was purified from the cell extract using metal affinity chromatography, as shown after SDS-PAGE blue staining, and was confirmed by immunoblotting using specific commercial monoclonal antibodies. In order to detect TEV–rhGH, in ELISA and immunoblotting, specific polyclonal antibody, with high titer (~ 10^− 5 fold dilution), was produced in a rabbit and purified using affinity chromatography. Preliminary tests have proved that TEV–rhGH protein and its specific purified IgG antibody could provide valuable tools for rhGH productive and diagnostic purposes.     

Cloning and expression of superoxide dismutase from Mycobacterium bovis BCG

We have previously purified the superoxide dismutase (SOD) of Mycobacterium bovis bacillus Calmette-Guerin (BCG), and there is no signal peptide necessary for protein exportation [S.K. Kang, Y.J. Jung, C.H. Kim, C.Y. Song, Extracellular and cytosolic iron superoxide dismutase from Mycobacterium bovis BCG, Clin. Diagn. Lab. Immunol. 5 (1998) 784-789]. In the present study, SOD gene of M. bovis BCG was cloned and expressed in Escherichia coli, and its complete nucleotide sequence and deduced amino acid composition were determined. The open reading frame from the GTG initiation codon was 621 base pair (bp) in length for the SOD structural gene. The ribosomal-binding sequences (GGAAGG) were 6-12 bp upstream from the initiation codon. The amino acid sequence, deduced from the nucleotide sequence, revealed that the SOD consists of 207 amino acids residues with a molecular weight of 22.8 kDa. The N-terminal amino acid sequence predicted from the nucleotide sequence showed that the structural gene of the SOD is not preceded by leader sequences. There were no cysteine residues in the deduced amino acid composition, indicating that the SOD does not consist of disulfide bonds. Analyses of both nucleotide and amino acid sequences of the SOD showed significant similarity to other pathogenic mycobacterial SODs. Furthermore, the results of fractionation and two-dimensional electrophoresis showed that SOD is also associated with cell membrane, suggesting that there might be a specific mechanism for exportation of SOD in M. bovis BCG as well as other pathogenic mycobacteria. Overexpressed SOD in E. coli was purified from the inclusion bodies, and the histidine tag was removed from the protein using enterokinase. Enzyme activity was then determined by gel staining analysis.     

Refolding and purification of non-fusion HPT protein expressed in Escherichia coli as inclusion bodies

The gene encoding hygromycin B phosphotransferase (hpt) is a widely used selectable marker in the production of genetically engineered crops. To facilitate the safety assessment of this protein, the non-fusion hpt expression plasmid was constructed and introduced into Escherichia coli to produce enough quantity of the HPT protein. High level expressed HPT was achieved but most of the expressed protein aggregated as inclusion bodies. The inclusion bodies were washed, separated from the cells, and solubilized by 0.3% Sarkosyl. The protein was renatured by dilution and dialysis, and then purified by anion-exchange chromatography. The activity is 8 U/mg protein and the purity is about 95%. Further studies showed that the microbially produced HPT protein had comparable molecular weight, immuno-reactivities, N-terminal amino acid sequences, and biological activities with those of the HPT produced by transgenic rice harboring hpt gene. All these results demonstrated the validity of utilizing the microbially produced HPT to assess the safety of the HPT protein produced in genetically engineered rice.     

Recombinant Human Cytomegalovirus Protease with a C-Terminal (His)6Extension: Purification, Autocatalytic Release of the Mature Enzyme, and Biochemical Characterization

Human cytomegalovirus protease (CMV PR) is a target for the development of antiviral therapeutics. To obtain large amounts of native protease, a 268-amino-acid polypeptide with a hexahistidinyl tag at the C terminus was expressed inEscherichia coli.The first 262 amino acids of the recombinant protein were identical to the amino acid sequence of native CMV PR, except for mutations introduced at the internal cleavage site to eliminate autoproteolysis at that site. The hexahistidinyl tag was placed downstream of amino acid 262 of the native CMV PR sequence. In this design, the Ala-Ser bond at amino acids 256–257 constitutes a site naturally cleaved by the protease during capsid maturation. The 268-amino-acid polypeptide with the (His)₆tag was expressed at high levels inE. colias inclusion bodies. After solubilization of the inclusion bodies, the protease was purified to homogeneity by a single step using Ni²⁺affinity chromatography. The protease was refolded to an active enzyme using dialysis which leads to effective autocleavage of the Ala-Ser bond at amino acids 256–257 to remove 12 amino acids including the (His)₆tag from the C terminus of the protein. This strategy yielded large amounts of highly purified CMV PR with the native N terminus and C terminus. Approximately 40 mg of purified CMV PR was obtained per liter of cell culture using this strategy. The enzymatic activity of CMV PR purified from inclusion bodies and refolded to an active enzyme was similar to the enzymatic activity of CMV PR expressed as a soluble protein inE. coli.In addition, the refolded CMV PR could be crystallized for X-ray diffraction.     

大肠杆菌表达的重组人PAI－1的纯化

纯化了工程细菌表达的可溶态和包含体形式的ｒｈＰＡＩ－１,纯度均达９８％,其ｒｈＰＡＩ－１蛋白质得率分别为１５％和１９％,比活性分别为３３５００ＩＵ／ｍｇ和２７７０００ＩＵ／ｍｇ。Ｎ端氨基酸序列分析显示,ｒｈＰＡＩ－１Ｎ端１５个氨基酸与天然ＰＡＩ－１完全一致;包含体复性研究表明,包含体的复性与复性蛋白的浓度及复性液中助溶剂的浓度密切相关。纯化的ｒｈＰＡＩ－１为分析ＰＡＩ－１结构与功能及探讨其临床应用提供了材料。     

Overproduction, purification, and characterization of Bacillus subtilis RNA polymerase sigma A factor.

By use of a T7 expression system, large amounts of active Bacillus subtilis RNA polymerase sigma A factor were produced in Escherichia coli cells. This overproduced protein was found in the form of inclusion bodies and constituted 40% of the total cellular protein. Because of the ease of isolation of the inclusion bodies and the acidic properties of sigma A, the protein was purified to more than 99% purity and the yield was about 90 mg/liter of culture. Gel mobility, antigenicity, specificity of promoter recognition, and N-terminal amino acid sequence of the overproduced sigma were found to be the same as those of native sigma A. Partial proteolysis analysis of sigma A protein suggested the presence of a protease-sensitive surface region in the C-terminal part of the sigma A protein. The promoter -10 binding region of sigma A was less sensitive to proteases and was probably involved in a hydrophobic, tightly folded domain of sigma A protein.